1. Re-election of Israel Makov, Nachum (Homi) Shamir, Doron Birger, Arie
Mientkavich, Dennert O. Ware and Prof. Anat Leowenstein as directors of
the company until the next Annual General Meeting of Shareholders;
2. Compensation of the President and Chief Executive Officer of the
Company;
3. Adoption of the Company's 2009 Equity Incentive Plan;
4. Extending the expiration term of certain stock options previously
granted to directors of the Company (other than the external directors
under Israeli law) under the Company's 2006 Equity Incentive Plan with
an expiration date of five years from the date of grant, by two
additional years until the seventh anniversary of the date of grant;
and
5. Re-appointment Somekh Chaikin, a member of KPMG International, as the
Company's independent auditors until the Company's next Annual General
Meeting of Shareholders and to authorize the Company's Audit Committee
and Board of Directors to determine their remuneration.
The board of directors wishes to thank shareholders for participating and
voting at this annual general meeting.
About Given Imaging
Given Imaging has advanced gastrointestinal diagnosis by developing
innovative, patient-friendly tools based on its PillCam® Platform.
PillCam capsule endoscopy provides physicians with natural images of the
small intestine via PillCam® SB, the esophagus through PillCam® ESO,
and the colon with PillCam® COLON [PillCam COLON is not cleared for use
in the USA]. The PillCam capsules are miniature video cameras that patients
ingest. Given Imaging's other capsule products include Agile™ patency
capsule, to verify intestinal patency, and Bravo®, the only wireless,
catheter-free, 48-hour pH test commercially available for pH testing to
assess gastroesophageal reflux disease (GERD). Given Imaging's products use
cutting-edge, wireless technology and advanced software to enable
gastroenterologists to better diagnose disease of the esophagus, small
bowel and colon and more accurately treat patients. All Given Imaging
products allow patients to maintain normal activities. Since 2001, more
than one million PillCam® video capsules have helped physicians evaluate
patients for GI disorders. Given Imaging's headquarters, manufacturing and
R&D facilities are located in Yoqneam, Israel, with operating subsidiaries
in the United States, Germany, France, Japan, Australia and Singapore. For
more information, please visit http://www.givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any future
events, results, performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to, the
following: (1) our ability to develop and bring to market new products, (2)
our ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (3) our success in
implementing our sales, marketing and manufacturing plans, (4) protection
and validity of patents and other intellectual property rights, (5) the
impact of currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of significant litigation, (8) our ability to
obtain reimbursement for our product from government and commercial payors,
(9) quarterly variations in operating results, (10) the possibility of
armed conflict or civil or military unrest in Israel, (11) the impact of
global economic conditions, and (12) other risks and factors disclosed in
our filings with the U.S. Securities and Exchange Commission, including,
but not limited to, risks and factors identified under such headings as
"Risk Factors," "Cautionary Language Regarding Forward-Looking Statements"
and "Operating Results and Financial Review and Prospects" in the Company's
Annual Report on Form 20-F for the year ended December 31, 2008. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Except for the
Company's ongoing obligations to disclose material information under the
applicable securities laws, it undertakes no obligation to release publicly
any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events.
Contact Information: For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 1-(866) GIVEN-IR